BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin

Reuters

2024-12-08

Dec 7 (Reuters) - Beam Therapeutics Inc :

* BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING

* BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

* BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2489221773"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489221773\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2489221773?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-08 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489221773","market":"us","top_or_hot":-1,"title":"BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin","media":"Reuters","content":"<html><body><p>Dec 7 (Reuters) - Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING</p><p>   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION</p><p>   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2024-12-08 00:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>Dec 7 (Reuters) - Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING</p><p>   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION</p><p>   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2489221773","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489221773","pubTimestamp":1733589003,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 7  - Beam Therapeutics Inc   :   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BRIEF-Beam Therapeutics表示，所有7名接受Beam-101治疗的患者均实现了胎儿血红蛋白的持久增加和镰状血红蛋白的减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":0.9,"LENZ":1},"content_text":"Dec 7 (Reuters) - Beam Therapeutics Inc   :   * BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL MEETING   * BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION   * BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101 ACHIEVED DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE HEMOGLOBIN Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}